查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1822646

避孕药市场机会、成长动力、产业趋势分析及 2025 - 2034 年预测

Contraceptives Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
出版日期: | 出版商: Global Market Insights Inc. | 英文 150 Pages | 商品交期: 2-3个工作天内

价格
简介目录

根据 Global Market Insights Inc. 发布的最新报告，全球避孕药具市场规模预计在 2024 年为 199 亿美元，预计将从 2025 年的 211 亿美元增长到 2034 年的 438 亿美元，复合年增长率为 8.4%。

避孕药市场 - IMG1

围绕生殖权利和计划生育的公共卫生运动和教育日益增多，提高了人们对避孕措施的认识和接受度。非政府组织和政府倡议（例如联合国人口基金会、世界卫生组织）正在推动已开发地区和发展中地区获得现代避孕措施。

市场范围
起始年份 2024
预测年份 2025-2034
起始值 199亿美元
预测值 438亿美元
复合年增长率 8.4%

设备采用率不断上升

受长效和可逆避孕需求不断增长的推动，2024年，避孕器械市场占据了显着份额。子宫内避孕器 (IUD)、保险套和植体等产品因其功效和便利性而日益受到青睐。其中，激素类和铜基IUD凭藉其高成功率和长期保护作用，仍是首选。市场参与者正专注于产品创新、提升舒适度和延长使用时间，以吸引更广泛的客户群。

15-44岁族群盛行率上升

15-44岁年龄层由于处于生育年龄且积极参与计划生育，在2024年占据了相当大的份额。这一年龄层的驱动力在于推迟怀孕的愿望以及青少年和年轻人日益增长的性健康意识。不断扩大的教育覆盖范围、数位健康平台以及有针对性的行销活动，正在帮助这一年龄层规范避孕措施的使用。各大公司正在调整其宣传讯息，强调生活方式的兼容性、易用性和可及性，以引起这一年龄层的共鸣。此外，为了吸引这一年龄层注重隐私的用户，该公司还推出了订阅模式和谨慎的配送服务。

零售药局将获得发展动力

2025-2034年，零售药局市场将以可观的复合年增长率成长，这得益于便利性、可近性和消费者匿名性。随着口服避孕药和应急药的非处方药供应日益增加，该市场正稳步成长。此外，药局营业时间的延长、城乡结合部地区渗透率的提高以及药剂师在生殖健康咨询中日益重要的作用也使该市场受益。为了增强影响力，製药公司正在与大型零售连锁店建立合作伙伴关係，提供促销折扣，并确保产品供应的稳定性。

区域洞察

北美将成为利润丰厚的地区

2024年，北美避孕药市场收入可观，这得益于消费者的高认知度、优惠的报销政策以及完善的医疗基础设施。由于荷尔蒙避孕药、子宫内避孕器和紧急避孕药的广泛应用，美国在该地区处于领先地位。根据最近的估计，北美市场价值超过80亿美元，并且随着数位处方和直接面向消费者的远距医疗服务的日益普及，预计将稳步增长。在该地区运营的公司专注于获得FDA批准、实现产品多元化以及扩展其线上销售平台，以满足不断变化的消费者行为。

避孕药市场的主要参与者有 HLL Lifecare（印度）、辉瑞、LifeStyles Healthcare、Church & Dwight、Exeltis、利洁时、CooperSurgical、Medintim（Kessel）、Organon、Pregna International、Evofem Biosciences、Mayne Pharma、Agile Therapeutics、拜耳、Ascience）。

为了维持并提升自身地位，避孕药市场中的公司正在采取一系列产品创新、区域扩张和以客户为中心的措施。其中最突出的策略之一是投资研发，以开发更安全、更有效、更方便使用者的产品，包括非荷尔蒙避孕药和男性避孕药。此外，各大品牌正在利用数位平台进行直接互动，提供远距医疗咨询和线上履行服务，以满足消费者对便利性的需求。

目录

第一章：方法论与范围

第二章：执行摘要

第三章：行业洞察

  • 产业生态系统分析
  • 产业衝击力
    • 成长动力
      • 已开发国家有利的监管环境
      • 计划性延迟妊娠的倾向日益增强
      • 发展中经济体未满足的避孕需求很高
      • 性传染病（STD）盛行率不断上升
    • 产业陷阱与挑战
      • 避孕药的副作用
    • 市场机会
      • 长效可逆避孕药（LARC）需求成长
      • 非荷尔蒙和天然避孕替代品的兴起趋势
  • 成长潜力分析
  • 监管格局
  • 技术格局
    • 当前的技术趋势
    • 新兴技术
  • 2024年定价分析
  • 消费者行为分析
  • 供应链分析
  • 品牌分析
  • 顶尖公司的商业模式
    • CooperSurgical
    • 利洁时
  • 市场进入策略分析
  • 差距分析
  • 波特的分析
  • PESTEL分析
  • 未来市场趋势
  • 价值链分析

第四章：竞争格局

  • 介绍
  • 公司矩阵分析
  • 公司市占率分析
    • 全球的
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 多边环境协定
  • 竞争定位矩阵
  • 主要市场参与者的竞争分析
  • 关键进展
    • 併购
    • 伙伴关係与合作
    • 新产品发布
    • 扩张计划

第五章：市场估计与预测：按产品，2021 - 2034 年

  • 主要趋势
  • 装置
    • 保险套
      • 男性
      • 女性
    • 子宫内避孕器
      • 荷尔蒙子宫内避孕器
      • 铜子宫内避孕器
    • 阴道环
    • 皮下植入物
    • 隔膜
    • 避孕海绵
  • 药物
    • 口服避孕药
    • 注射避孕药
    • 外用避孕药

第六章：市场估计与预测：按年龄组，2021 - 2034 年

  • 主要趋势
  • 15 - 44岁
  • 44岁以上

第七章：市场估计与预测：按配销通路，2021 - 2034 年

  • 主要趋势
  • 零售药局
  • 医院药房
  • 线上通路
  • 其他分销管道

第八章：市场估计与预测：按地区，2021 - 2034 年

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 荷兰
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第九章：公司简介

  • Agile Therapeutics
  • Bayer
  • Church & Dwight
  • CooperSurgical
  • Evofem Biosciences
  • Exeltis
  • HLL Lifecare (India)
  • HRA Pharma / Perrigo (OTC)
  • LifeStyles Healthcare
  • Mayne Pharma
  • Medintim (Kessel)
  • Organon
  • Pfizer
  • Pregna International
  • Reckitt
简介目录
Product Code: 430

The global contraceptives market was estimated at USD 19.9 billion in 2024 and is expected to grow from USD 21.1 billion in 2025 to USD 43.8 billion by 2034, at a CAGR of 8.4%, according to the latest report published by Global Market Insights Inc.

Contraceptives Market - IMG1

Growing public health campaigns and education around reproductive rights and family planning are increasing awareness and acceptance of contraceptives. NGOs and government initiatives (e.g., UNFPA, WHO) are promoting access to modern contraceptives in both developed and developing regions.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$19.9 Billion
Forecast Value$43.8 Billion
CAGR8.4%

Rising Adoption of Devices

The devices segment held a notable share in 2024, driven by the growing demand for long-acting and reversible contraceptive options. Products such as intrauterine devices (IUDs), condoms, and implants are increasingly favored for their efficacy and convenience. Among these, hormonal and copper-based IUDs remain the top choices due to their high success rates and long-term protection. Market players are focusing on product innovation, enhanced comfort, and extended duration of use to attract a wider customer base.

Increasing Prevalence Among 15-44 Years

The 15-44 years segment held a sizeable share in 2024 owing to their reproductive age and active participation in family planning. This segment is driven by the desire to delay pregnancies and the rising need for sexual health awareness among adolescents and young adults. Increased educational outreach, digital health platforms, and targeted marketing campaigns are helping to normalize contraceptive use among this demographic. Companies are tailoring their messaging to resonate with this audience by emphasizing lifestyle compatibility, ease of use, and access. Subscription models and discreet delivery services have also been introduced to appeal to privacy-conscious users in this segment.

Retail Pharmacies to Gain Traction

The retail pharmacies segment will grow at a decent CAGR during 2025-2034, backed by convenience, accessibility, and anonymity to consumers. With the growing over-the-counter availability of oral contraceptives and emergency pills, this segment is witnessing steady growth. The segment also benefits from extended pharmacy hours, growing penetration in semi-urban areas, and pharmacists' increasing role in reproductive health counseling. To strengthen their presence, pharmaceutical companies are forming partnerships with major retail chains, offering promotional discounts, and ensuring consistent product availability.

Regional Insights

North America to Emerge as a Lucrative Region

North America contraceptives market generated significant revenues in 2024, supported by high consumer awareness, favorable reimbursement policies, and robust healthcare infrastructure. The United States leads the region due to the widespread adoption of hormonal contraceptives, IUDs, and emergency contraceptive pills. As of recent estimates, the market in North America was valued at over USD 8 billion and is projected to grow steadily with the increasing availability of digital prescriptions and direct-to-consumer telehealth services. Companies operating in this region are focused on FDA approvals, product diversification, and expanding their online sales platforms to meet evolving consumer behavior.

Major players in the contraceptives market are HLL Lifecare (India), Pfizer, LifeStyles Healthcare, Church & Dwight, Exeltis, Reckitt, CooperSurgical, Medintim (Kessel), Organon, Pregna International, Evofem Biosciences, Mayne Pharma, Agile Therapeutics, Bayer, HRA Pharma / Perrigo (OTC).

To maintain and grow their position, companies in the contraceptives market are employing a mix of product innovation, regional expansion, and customer-centric initiatives. One of the most prominent strategies involves investing in R&D to develop safer, more effective, and user-friendly products, including non-hormonal and male contraceptive options. Additionally, brands are leveraging digital platforms for direct engagement, offering telehealth consultations and online fulfillment services to meet the demand for convenience.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Data mining sources
    • 1.3.1 Global
    • 1.3.2 Regional/country
  • 1.4 Base estimates and calculations
    • 1.4.1 Base year calculation
    • 1.4.2 Key trends for market estimation
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
  • 1.6 Forecast model
  • 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

  • 2.1 Industry 3600 synopsis
  • 2.2 Key market trends
    • 2.2.1 Regional trends
    • 2.2.2 Product trends
    • 2.2.3 Age group trends
    • 2.2.4 Distribution channel trends
  • 2.3 CXO perspectives: Strategic imperatives
    • 2.3.1 Key decision points for industry executives
    • 2.3.2 Critical success factors for market players
  • 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Favourable regulatory scenario in developed nations
      • 3.2.1.2 Growing inclination towards planned delayed pregnancy
      • 3.2.1.3 High unmet contraceptive needs in developing economies
      • 3.2.1.4 Increasing prevalence of sexually transmitted diseases (STD)
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 Adverse effects of contraceptive drugs
    • 3.2.3 Market opportunities
      • 3.2.3.1 Growth in demand for long-acting reversible contraceptives (LARCs)
      • 3.2.3.2 Rising trend of non-hormonal and natural contraceptive alternatives
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
    • 3.4.1 North America
    • 3.4.2 Europe
    • 3.4.3 Asia Pacific
    • 3.4.4 Latin America
    • 3.4.5 MEA
  • 3.5 Technology landscape
    • 3.5.1 Current technological trends
    • 3.5.2 Emerging technologies
  • 3.6 Pricing analysis, 2024
  • 3.7 Consumer behaviour analysis
  • 3.8 Supply chain analysis
  • 3.9 Brand analysis
  • 3.10 Business model of top companies
    • 3.10.1 CooperSurgical
    • 3.10.2 Reckitt
  • 3.11 Go-to-Market strategy analysis
  • 3.12 Gap analysis
  • 3.13 Porter's analysis
  • 3.14 PESTEL analysis
  • 3.15 Future market trends
  • 3.16 Value chain analysis

Chapter 4 Competitive Landscape, 2024

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Company market share analysis
    • 4.3.1 Global
    • 4.3.2 North America
    • 4.3.3 Europe
    • 4.3.4 Asia Pacific
    • 4.3.5 Latin America
    • 4.3.6 MEA
  • 4.4 Competitive positioning matrix
  • 4.5 Competitive analysis of major market players
  • 4.6 Key developments
    • 4.6.1 Mergers and acquisitions
    • 4.6.2 Partnerships and collaborations
    • 4.6.3 New product launches
    • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2034 ($ Mn)

  • 5.1 Key trends
  • 5.2 Devices
    • 5.2.1 Condoms
      • 5.2.1.1 Male
      • 5.2.1.2 Female
    • 5.2.2 Intra-uterine devices
      • 5.2.2.1 Hormonal IUD
      • 5.2.2.2 Copper IUD
    • 5.2.3 Vaginal rings
    • 5.2.4 Subdermal implants
    • 5.2.5 Diaphragms
    • 5.2.6 Contraceptive sponges
  • 5.3 Drugs
    • 5.3.1 Oral contraceptive pills
    • 5.3.2 Injectable contraceptives
    • 5.3.3 Topical contraceptives

Chapter 6 Market Estimates and Forecast, By Age Group, 2021 - 2034 ($ Mn)

  • 6.1 Key trends
  • 6.2 15 - 44 years
  • 6.3 Above 44 years

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2034 ($ Mn)

  • 7.1 Key trends
  • 7.2 Retail pharmacies
  • 7.3 Hospital pharmacies
  • 7.4 Online channels
  • 7.5 Other distribution channels

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

  • 8.1 Key trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Spain
    • 8.3.5 Italy
    • 8.3.6 Netherlands
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Argentina
  • 8.6 Middle East and Africa
    • 8.6.1 South Africa
    • 8.6.2 Saudi Arabia
    • 8.6.3 UAE

Chapter 9 Company Profiles

  • 9.1 Agile Therapeutics
  • 9.2 Bayer
  • 9.3 Church & Dwight
  • 9.4 CooperSurgical
  • 9.5 Evofem Biosciences
  • 9.6 Exeltis
  • 9.7 HLL Lifecare (India)
  • 9.8 HRA Pharma / Perrigo (OTC)
  • 9.9 LifeStyles Healthcare
  • 9.10 Mayne Pharma
  • 9.11 Medintim (Kessel)
  • 9.12 Organon
  • 9.13 Pfizer
  • 9.14 Pregna International
  • 9.15 Reckitt